Please login to the form below

brodalumab

This page shows the latest brodalumab news and features for those working in and with pharma, biotech and healthcare.

Sun Pharma passes milestone with novel psoriasis drug approval

IL-23-selective follow-up Tremfya (guselkumab) as well as three IL-17 inhibitors - Novartis’ Cosentyx (secukinumab), Eli Lilly’s Taltz (ixekizumab) and Valeant Pharma’s Siliq (brodalumab).

Latest news

AbbVie reports more solid data for would-be psoriasis blockbuster

ixekizumab) and Valeant’s Siliq (brodalumab).
Lilly claims another EU okay for Taltz

leader. A third IL-17 drug - Valeant’s Siliq (brodalumab) - was launched in the third quarter in the US at a discount to Cosentyx and Taltz but the company has yet
European Commission backs LEO Pharma’s Kyntheum

Novel biologic therapies such as brodalumab mean that achieving completely clear skin can now be a reality for people with moderate-to-severe psoriasis.”. ... Additionally, across all three trials, 56-61% of patients reported the skin condition no
Biosimilars eat into J&J's Remicade sales

brodalumab) - which claimed an earlier-than-expected FDA approval for psoriasis last week.
Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Meanwhile among other positive opinions granted by the CHMP was one for Leo Pharma's interleukin-17 inhibitor Kyntheum (brodalumab) - acquired from AstraZeneca - for plaque psoriasis.

More from news
Approximately 9 fully matching, plus 32 partially matching documents found.

Latest Intelligence

Pharma deals in September 2015

Brodalumab is phase III complete, but is thought to have been cast off due to concerns raised over links to the drug and suicidal thoughts. ... Collaboration - discovery. 500. AstraZeneca. Valeant Pharmaceuticals. Brodalumab for psoriasis, ready for

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Creative/ Medical Writer: Circa £35, 000 With Benefits

Senior Account Director – Healthcare Advertising – London: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Programme/ Account Director - Healthcare PR - London: Salary TBC

Health Consultant - Brand Comms: Competitive Salary

Home-based Senior Medical Writer – Med Ed: Salary TBC

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Scientific Director – Medical Communications: Salary TBC

Account Director, Medical Education: Salary TBC

EU Head of Business Development and Client Service: Exceptional packge and bonus

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Associate Director – Social Healthcare – London: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Home based, Senior Medical Writer, Medical Communications: Excellent package

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Senior Medical Writer: Salary TBC

Managing Director – Global Medical Writing & Scientific Exce...: £120-150K

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Home-based Medical Writer – Medical Education: Salary TBC

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

AM – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

Senior Account Manager, Medical Communications, London: Excellent package

Senior Digital Health Specialist – Global Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience: Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution: Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence: Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....